drugset
drugset / Trial / NCT02284828

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

NCT02284828 ↗

Phase 1 Completed 26 enrolled Bial - Portela C S.A.
NaSingle-groupSingle-blindTreatment

Summary

Single-blind, single-centre, fixed-order study to evaluate the PD effects of a single oral dose and multiple oral doses of ESL (BIA 2-093) in healthy volunteers.

Timeline

Start
2007-09
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 800 mg Oral
Subject Eslicarbazepine acetate Unknown 900 mg Oral
Subject Eslicarbazepine acetate Unknown 1200 mg Oral

Indications

epilepsy